<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01663389</url>
  </required_header>
  <id_info>
    <org_study_id>112167</org_study_id>
    <nct_id>NCT01663389</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose</brief_title>
  <official_title>An Open Label, Non-Randomized, Single Dose, Two Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, non-randomized, open label, single-dose, two-period, cross-over study.&#xD;
      This study will utilize 14C radiolabeled GSK1322322 to investigate the recovery, excretion,&#xD;
      and pharmacokinetics of GSK1322322 in 6 healthy adult male subjects through the sampling of&#xD;
      blood, urine, and feces.&#xD;
&#xD;
      Each subject will participate in the study for approximately 7 to 8 weeks i.e., 30 day&#xD;
      screening period, two dosing periods (approximately 8 days each) and a follow up visit.&#xD;
&#xD;
      The subjects will be admitted to the clinical unit on Day 1 of the first treatment period and&#xD;
      remain in the unit for up to approximately 16 days through the end of the second treatment&#xD;
      period.&#xD;
&#xD;
      On Day 1 of Period 1, each subject will receive 14C radiolabeled GSK1322322 as a single&#xD;
      therapeutic intravenous (IV) dose (1000 milligrams [mg]). When the total radioactivity is &lt;1%&#xD;
      of the administered dose in all subjects, Period 2 dosing will begin (approximately 8 days&#xD;
      after the IV dose). On Day 1 of Period 2, each subject will receive single therapeutic oral&#xD;
      solution dose (1200 mg). Blood, urine, bile and fecal samples will be collected during both&#xD;
      the periods. The subject may be discharged from the unit as early as Day 8 of Period 2.&#xD;
      Subjects will visit the study unit for the follow-up visit 7 to 10 days following discharge&#xD;
      from the unit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2012</start_date>
  <completion_date type="Actual">October 5, 2012</completion_date>
  <primary_completion_date type="Actual">October 5, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameters of GSK1322322 and radiolabeled compound following single IV or oral solution dose: AUC(0-infinity), AUC(0-t), Cmax, tmax, t1/2 for IV and oral solution regimens and CL and Vss for IV regimen only</measure>
    <time_frame>Day 1 through Day 8 of Period 1 and Period 2 (16 days)</time_frame>
    <description>Plasma PK parameters will be statistically summarized by treatment. Plasma concentration-time data will be analyzed by non-compartmental methods. Following PK parameters will be studied: Area under the concentration-time curve (AUC) from time zero (pre-dose) extrapolated to infinite time [AUC(0-infinity)], AUC(0-t), maximum observed concentration (Cmax), time of occurrence of Cmax (tmax), terminal phase half-life (t1/2) for IV and oral solution regimens and systemic clearance (CL) and volume of distribution (Vss) for IV regimen only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent total recovery of radioactivity in urine and feces in each interval and cumulative</measure>
    <time_frame>Day 1 through Day 8 (and additional days, if required) of Period 1 and Period 2 (16 days or more)</time_frame>
    <description>Total recovery of radioactivity in urine and feces (as a percentage of total radioactive dose in each interval and cumulative)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety parameters including adverse events, clinical laboratory tests, concomitant medications, electrocardiograms, and vital signs</measure>
    <time_frame>Duration of the study (56 days)</time_frame>
    <description>To evaluate the safety and tolerability of GSK1322322 after single IV and oral solution doses in healthy subjects safety parameters will be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Infections, Bacterial</condition>
  <arm_group>
    <arm_group_label>GSK1322322 1000 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of Period 1, after an overnight fast, subjects will receive GSK1322322 1000 mg IV single dose (containing approximately 45.5 microcurie [μCi] radioactive 14C-GSK1322322) for intravenous infusion over 60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1322322 1200 mg Oral Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of Period 2, after an overnight fast, subjects will receive GSK1322322 1200 mg oral solution single dose (containing approximately 54.5 μCi radioactive 14C-GSK1322322).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1322322 1000 mg containing radioactive 14C-GSK1322322</intervention_name>
    <description>GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.</description>
    <arm_group_label>GSK1322322 1000 mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1322322 1200 mg containing radioactive 14C-GSK1322322</intervention_name>
    <description>GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.</description>
    <arm_group_label>GSK1322322 1200 mg Oral Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects between 30 and 55 years of age, with body weight between 60 to&#xD;
             80 kilograms (kg) and a history of regular bowel movements&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use one of&#xD;
             the contraception methods from first dose of study medication until the final follow&#xD;
             up visit&#xD;
&#xD;
          -  Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin =&lt;1.5x upper limit&#xD;
             of normal&#xD;
&#xD;
          -  QT interval by Bazett's correction formula (QTcB) &lt;450 millisecond (msec); or QTcB&#xD;
             &lt;480 msec in subjects with Bundle Branch Block&#xD;
&#xD;
          -  Available to complete the study and return for follow-up visits if necessary&#xD;
&#xD;
          -  Capable of giving written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition that could interfere with the accurate assessment and recovery of&#xD;
             radioactivity [14C]&#xD;
&#xD;
          -  Participation in a clinical trial involving administration of radiolabeled&#xD;
             14C-labelled compound(s) within the last 12 months&#xD;
&#xD;
          -  Any condition which impairs the absorption, distribution, metabolism or excretion of&#xD;
             the investigational product&#xD;
&#xD;
          -  Subjects with a history of cholecystectomy&#xD;
&#xD;
          -  Subject has received a total body radiation dose of greater than 5.0 millisievert&#xD;
             (mSv) or exposure to significant radiation during 1 year before dosing&#xD;
&#xD;
          -  The subject has a positive: drug/alcohol, Hepatitis, HIV screen&#xD;
&#xD;
          -  Abuse of alcohol&#xD;
&#xD;
          -  History of liver disease, or known hepatic or biliary abnormalities&#xD;
&#xD;
          -  The subject has recently received an investigational product&#xD;
&#xD;
          -  Donation of more than 500 mL blood within a 56 day period&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia&#xD;
&#xD;
          -  Smoking or history or regular use of tobacco or nicotine-containing products&#xD;
&#xD;
          -  Unable to refrain from consumption of red wine, Seville oranges, grapefruit or&#xD;
             grapefruit juice from 7 days prior to the first dose&#xD;
&#xD;
          -  History of cardiac disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>August 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2012</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mass balance</keyword>
  <keyword>radiolabel</keyword>
  <keyword>oral</keyword>
  <keyword>IV</keyword>
  <keyword>GSK1322322</keyword>
  <keyword>healthy volunteer</keyword>
  <keyword>antibiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112167</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112167</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112167</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112167</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112167</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112167</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112167</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

